Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$42.98 USD

42.98
17,140,067

+0.31 (0.73%)

Updated Jul 23, 2024 04:00 PM ET

After-Market: $42.98 0.00 (0.00%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Bristol Myers Squibb (BMY) Stock Moves -0.81%: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed the most recent trading day at $70.71, moving -0.81% from the previous trading session.

Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More

by Zacks Equity Research

Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.

Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib

by Zacks Equity Research

Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.

Bristol Myers (BMY) Skin Cancer Drug Gets EC's Approval

by Zacks Equity Research

Bristol Myers (BMY) gets EC approval for the fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor Opdivo (nivolumab and novel LAG-3-blocking antibody relatlimab.

Should Invesco Dynamic Large Cap Value ETF (PWV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for PWV

Bristol Myers Squibb (BMY) Stock Moves -0.36%: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $71.52 in the latest trading session, marking a -0.36% move from the prior day.

Bristol Myers' (BMY) Opdivo Meets Main Goal in Melanoma Study

by Zacks Equity Research

Bristol Myers' (BMY) immuno-oncology drug Opdivo demonstrates a statistically significant and clinically meaningful improvement in recurrence-Free survival (RFS) in patients with Stage IIB/C melanoma.

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $70.47, marking a -0.8% move from the previous day.

Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More

by Zacks Equity Research

Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.

Syros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer Drug

by Zacks Equity Research

Syros Pharmaceuticals (SYRS) receives Orphan Drug designation from the FDA for its pipeline candidate AY-5609 being developed for treating metastatic pancreatic cancer. Stock up.

Company News for Sep 13, 2022

by Zacks Equity Research

Companies in The News Are: AAPL, BMY, TWTR, GILD

Is Most-Watched Stock Bristol Myers Squibb Company (BMY) Worth Betting on Now?

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PWV

Bristol Myers (BMY) Gets FDA Approval for Psoriasis Candidate

by Zacks Equity Research

Bristol Myers (BMY) secures an FDA nod for Sotyktu to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $69.38 in the latest trading session, marking a +0.9% move from the prior day.

Exelixis (EXEL) Reports Positive Cabometyx Combo Study Results

by Zacks Equity Research

Exelixis (EXEL) announces positive detailed results on the triplet combination study of Cabometyx, Opdivo and Yervoy.

Bristol Myers Squibb (BMY) Stock Moves -0.69%: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $68.61 in the latest trading session, marking a -0.69% move from the prior day.

Biotech Stock Roundup: BMY's Study Update, INCY's Drug Label Expansion, MRNA News

by Zacks Equity Research

Regulatory updates from Bristol Myers (BMY) and Incyte (INCY) are a few key highlights from the biotech sector during the past week.

Bristol Myers (BMY) Announces Milvexian Phase II Study Results

by Zacks Equity Research

Bristol Myers (BMY) announces AXIOMATIC-SSP study results of milvexian, an investigational oral factor XIa inhibitor, for preventing new symptomatic ischemic stroke or new covert brain infarction.

The Zacks Analyst Blog Highlights Apple, Alibaba, Bristol-Myers Squibb, Tesla and Cigna

by Zacks Equity Research

Apple, Alibaba, Bristol-Myers Squibb, Tesla and Cigna are part of The Zacks top Analyst Blog.

Mark Vickery headshot

Top Analyst Reports for Apple, Alibaba & Bristol-Myers Squibb

by Mark Vickery

Today's Research Daily features new research reports on 12 major stocks, including Apple Inc. (AAPL), Alibaba Group Holding Limited (BABA) and Bristol-Myers Squibb Company (BMY).

Iovance (IOVA) Starts Rolling BLA With FDA for Melanoma Therapy

by Zacks Equity Research

Iovance (IOVA) starts a rolling BLA submission with the FDA seeking approval for its lead pipeline candidate in advanced melanoma patients. The filing is expected to be completed by fourth-quarter 2022.

Bristol Myers (BMY) Up 14.6% YTD: Will the Performance Continue?

by Zacks Equity Research

Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue on label expansion of existing drugs.

Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SPYD

bluebird bio (BLUE) Focused on Pipeline Amid Marketed Drug Dearth

by Zacks Equity Research

bluebird bio's (BLUE) efforts to develop its gene-therapy pipeline are impressive. The FDA is reviewing BLUE's filing for beti-cel as a treatment for beta thalassemia and eli-cel for cerebral adrenoleukodystrophy.